C. Swearingen

Author Of 4 Presentations

Podium Presentation Osteoarthritis

13.3.4 - A 52 week Randomized, Double-Blind Phase 2 Study Of Intra-Articular, Wnt Pathway Inhibitor (SM04690) For Osteoarthritis (ID 9588)

Presentation Number
13.3.4
Topic
Osteoarthritis
Lecture Time
13:57 - 14:06
Disclosure
A.Gomoll, NuTech, Consultant M.Jones, Samumed, Consultant S.Kennedy, Samumed, Employee,Shareholder I. Simsek, Samumed, Employee, Shareholder C.Swearingen, Samumed, Employee,Shareholder J.Tambiah, Samumed, Employee, Shareholder
Podium Presentation Osteoarthritis

13.4.3 - Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: P2 Post-hoc Data From Wnt Pathway Inhibitor, SM04690 (ID 9669)

Presentation Number
13.4.3
Topic
Osteoarthritis
Lecture Time
13:39 - 13:48
Disclosure
A.Brett, M.Bowes, iMorphics, Employee P.Conaghan, Flexion, AbbVie, Infirst, Medivir, EMDSerono, Novartis, ONO, Consultancy C.Lattermann, Samumed, Vericel, Cartiheal, Consultancy; ICRS, Board; AJSM, Cartilage, JKS, Ort J Sports Med, Reviewer S.Kennedy, C.Swearingen, J.Tambiah, Samumed, Employee
Podium Presentation Osteoarthritis

21.3.1 - SM04690, A Wnt Pathway Inhibitor: Anti-Inflammatory And Cartilage Protective Effects In Preclinical OA Models (ID 9672)

Presentation Number
21.3.1
Topic
Osteoarthritis
Lecture Time
14:15 - 14:24
Disclosure
V. Deshmukh, Samumed LLC, Employee, Shareholder T.Seo, Samumed LLC, Employee, Shareholder C.Swearingen, Samumed LLC, Employee, Shareholder Y.Yazici, Samumed LLC, Employee, Shareholder
Extended Abstract (for invited Faculty only) Clinical Outcome

27.1.3 - Radiographic Outcomes were Concordant with Pain and Function Response: Post-hoc Analysis from a Phase 2 Study of SM04690, a WNT Pathway Inhibitor for Knee Osteoarthritis Treatment (ID 10586)

Presentation Number
27.1.3
Topic
Clinical Outcome
Lecture Time
12:24 - 12:36
Disclosure
C. Swearingen, Samumed, LLC, employee and shareholder S. Kennedy, Samumed, LLC, employee and shareholder J. Tambiah, Samumed, LLC, employee and shareholder